Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
|
|
- Brandon Gibbs
- 5 years ago
- Views:
Transcription
1 Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA
2 Associations of Obesity with Overall & Breast Cancer Specific Survival
3 Survival Obese vs. Non-obese Breast Cancer Patients by Hormone Receptor Niraula et al. BCRT 2012;134:769-81
4 Survival Obese vs. Non-obese Breast Cancer Patients by Menopausal Status Niraula et al. BCRT 2012;134:769-81
5 Breast Cancer Specific Survival Obese vs. Non-obese Breast Cancer Patients by Hormone Receptor Niraula et al. BCRT 2012;134:769-81
6 Breast Cancer Specific Survival Obese vs. Non-obese Breast Cancer Patients by Menopausal Status Niraula et al. BCRT 2012;134:769-81
7 BMI & Recurrence: Non-inflammatory Locally Advanced and Inflammatory: MD Anderson (N=602) Dawood S et al. Clin Cancer Res 2008;14: by American Association for Cancer Research
8 Obesity & Treatments
9 Obesity in N 0, ER+ Breast Cancer: Tamoxifen Efficacy
10 Survival by BMI: Neoadjuvant Breast Cancer Patients MD Anderson Series Litton, J. K. et al. J Clin Oncol; 26: Copyright American Society of Clinical Oncology
11 BMI in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: BIG trial, N=2,887 A: overall survival B: disease-free survival de Azambuja et al. Br Ca Res Treat 2009
12 Overweight/obese by Treatment (tamoxifen, anastrozole) & Survival: ABCSG-12 Trial (n=1803 Premenopausal Patients) Pfeiler G et al. JCO 2011;29: by American Society of Clinical Oncology
13 ATAC Trial Anastrozole vs Tamoxifen by BMI: All & Distant Recurrences Sestak I et al. JCO 2010;28: by American Society of Clinical Oncology
14 Weight Change after Diagnosis and Breast Cancer Prognosis 4/8 studies: significant decreased survival/ increased recurrence with weight gain Nurses Health Study, n=5204, followed ~ 9 years, risk or death for BMI gain in non-smokers: kg/m 2 : 1.35 > 2.0 kg/m 2 : 1.64 LACE cohort, stage 1-3, n=1689, followed ~ 7 years Weight loss > 10%: 2.5 x increased risk of death in ER- /PR- patients Chlebowski, Aiello, McTiernan JCO 2002;20(4): Kroenke et al. J. Clin Onc 2005;23(7): Caan B et al. Ca Causes Cont 2008:19:
15 Other Potential Adverse Effects of Obesity in Breast Cancer Wound complications Lymphedema Radiation therapy challenges? Endometrial cancer in tamoxifen users Congestive heart failure in patients treated with doxorubicin Increased risk for coronary disease, diabetes, stroke, hypertension, osteoarthritis, several cancers, decreased quality of life
16 Weight & Prognosis: Summary Overweight/obese/underweight prognosis Weight gain after diagnosis Purposeful weight loss after diagnosis???
17 Weight & Prognosis: Summary Associations seen in: Pre-menopausal Postmenopausal All stages Hormone receptor positive & negative Varied treatments including surgery, chemotherapy, hormonal agents Population & clinical trial cohorts Chlebowski, Aiello, McTiernan JCO 2002;20(4): Niraula et al. BCRT 2012;134:769-81
18 Potential Mechanisms of Obesity- Prognosis Link Estrogens, androgens Hyper-insulinemia, insulin resistance, diabetes, pre-diabetes Inflammatory markers Diet/physical activity Inadequate chemotherapy dosing
19 Chemotherapy Dosing: ASCO Guidelines Up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Full weight based cytotoxic chemotherapy doses should be used to treat obese patients with cancer. No evidence that short or long-term toxicity is increased among obese patients receiving full weight based doses. Griggs et al. JCO 2012; 30(13):
20 HEAL Cohort 1183 newly diagnosed breast cancer patients 3 centers: FHCRC, New Mexico, Los Angeles Population-based (registries) Multi-ethnic Followed for ~ 10 years post-diagnosis Assessing effect on prognosis of: weight, physical activity, metabolic hormones, inflammation, sex hormones, nutrition, vitamin D
21 Hazard Ratio Risk of Breast Cancer Death by C-peptide (HEAL, 571 stage I-IIIa patients, followed up mean 4.1 years) C-peptide P trend = 0.03 < 1.7 ng/ml ng/ml > 2.5 ng/ml Diabetics Irwin et al. J Clin Oncol 2011; 29(1):47-53
22 Fasting Glucose and Breast Cancer Outcomes Population: 512 early stage breast cancer no known diabetes Results: Quartile DDFS OS Mean Range HR (adjusted)* (95% CI) HR (adjusted)* (95% CI) ( ) 1.26 ( ) ( ) 1.46 ( ) ( ) 1.81 ( ) p=0.027 unadjusted p=0.034 adjusted p=0.036 unadjusted p=0.014 adjusted * adjusted for age, T, N, grade, hormone receptor, chemotherapy, hormone therapy Goodwin PJ et al. J Clin Oncol 2012
23 Hazard Ratio Risk of Death by C-Reactive Protein (HEAL, 734 stage I-IIIa patients, followed up mean 3.8 years) 2.5 P trend = < 1.2 mg/l mg/l > 3.9 mg/l Met-hr/wk Pierce et al. J Clin Oncol 2009; 27(21):
24 HEAL Study Weight Change (kg) in 2 Years after Diagnosis, by Stage P=0.004 Stage in situ Stage I Stage II-IIIa Irwin, M. L. et al. J Clin Oncol; 23:
25 Low-Fat Diet and Breast Cancer Prognosis: the WINS Study Clinical trial 2,437 women with early stage breast cancer Recruited from 37 U.S. sites years old Randomly assigned to low-fat diet or control group 6 lb. greater weight loss at 12 mos. in intervention vs. control women Followed for up to 5 years Risk of death was significantly reduced by 24 percent in diet patients vs. controls
26 High Vegetable/Lower Fat Diet: Multi-site clinical trial the WHEL Study 3088 women with early stage breast cancer years old Randomly assigned to high vegetable/fruit/fiber, low-fat diet or control group Followed for a mean 7.3 years Little change in diet vs. control diets No effect of diet on prognosis Pierce et al. JAMA Jul 18;298(3):
27 Alcohol & Breast Cancer Prognosis Recent findings suggest alcohol use (> 1 drink/d) associated with: Increased recurrence Increased contralateral/2 nd primary breast cancer Moderate alcohol use may be associated with reduced mortality Li et al. JCO 2009;27: Kwan et al. JCO 2010;28(29): Barnett et al. JCO 2008; 26:
28 Physical Activity & Breast Cancer Survival Ballard-Barbash R, et al. JNCI Jun 6;104(11):815-40
29 Exercise Effects in Breast Cancer Survivors Aerobic exercise: Improves fitness, mood, overall quality of life Reduces weight (moderately) and fatigue Increases lean mass Resistance (strength) training: Decreases lymphedema episodes & symptoms Increases strength Combined aerobic + resistance: Decreases arthralgia in aromatase inhibitor users Galvao et al. JCO 2005;23: (review). Schmitz K et al. N Engl J Med 2009;361: Courneya et al. JNCI 2013 Dec 4;105(23): Irwin ML et al. JCO (in press)
30 Hours/week Total Physical Activity Before and After Diagnosis in Breast Cancer Survivors by Treatment (HEAL) P<.05 Surgery Surgery + Radiation Treatment P<.05 Surgery + Chemo Irwin M. et al. Cancer 2003;97: Before Diagnosis After Diagnosis
31 Treatments Available for Conditions (None FDA Approved for Breast Cancer) Reduce/treat obesity: Reduced calorie diet Physical activity Weight loss therapies (extreme obesity or co-morbidities) Xenical/Alli (orlistat, blocks fat absorption prescription & OTC) Qsymia (topiramate, an anti-convulsant & phentermine, an appetite suppressant) Belviq (lorcaserin hydrochloride, activates serotonin 2C receptor) Bariatric surgery Note: all for adding to diet & exercise weight loss program Medications to treat obesity mediators: Excess insulin (Metformin - NCIC trial ongoing) Inflammation (Statins, NSAIDS)
32 Implementing Lifestyle Change Reduced calorie (~ kcal/day) Increased physical activity (>150 minutes/week moderate intensity) Strength training does not increase lymphedema (progress slowly) Weekly meetings with counselor Self-monitoring: Daily diet logs all foods and drinks Weighing at least weekly Daily exercise logs - recreational/walking activity Goal 7%-10% weight loss in 6 months Studies in breast cancer survivors show lower weight loss than in persons without cancer
33 Conclusions: Clinical Guidelines During chemo/radiation: Avoid weight gain unless underweight Exercise as tolerated: start slowly, increase slowly After or no chemo/radiation: Lose weight if BMI > 25.0 through calorie reduction + increased physical activity Aerobic exercise at least 30 min/day, 5 days/wk Gradually increase to moderate intensity (e.g. brisk walking, biking, fast dancing) Long-term survivors: weight loss may lower adverse prognosis biomarkers Keep alcohol to 1 drink/day or less
Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA Associations of Obesity with Overall & Breast Cancer Specific Survival Survival Obese vs. Non-obese
More informationLifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival
Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Melinda L. Irwin, PhD, MPH Associate Professor of Epidemiology Yale School of Medicine
More informationPhysical Activity & Cancer What We Know, What We Don t Know. Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA
Physical Activity & Cancer What We Know, What We Don t Know Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA What We Know Extensive epidemiologic research on relationship between
More informationLifestyle Risk Factors and Cancer Prevention
February 3-5, 2016 Lansdowne Resort, Leesburg, VA Lifestyle Risk Factors and Cancer Prevention Melinda L. Irwin, PhD, MPH Professor of Epidemiology, Yale School of Public Health, Associate Director (Population
More informationObesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J. Goodwin
VOLUME 34 NUMBER 35 DECEMBER 10, 2016 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J.
More informationBreast Cancer Survivorship
Breast Cancer Survivorship Melissa Accordino, MD Assistant Professor of Medicine Herbert Irving Comprehensive Cancer Center Columbia University Medical Center Who are the Cancer Survivors? More than 1
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationEvidence for the Role of Obesity in Breast Cancer Progression
Evidence for the Role of Obesity in Breast Cancer Progression Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C. Professor of Medicine Mount Sinai and Princess Margaret Hospitals University of Toronto BMI and
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationEating and Exercising toward Better Health in Cancer Survivors
W O R K I N G E V E R Y D A Y T O P R O V I D E T H E H I G H E S T Q U A L I T Y O F L I F E F O R P E O P L E W I T H C A N C E R Eating and Exercising toward Better Health in Cancer Survivors W E N
More informationPamela J. Goodwin, M.D., M.Sc., F.R.C.P.C.
Overview of the Evidence Relating Cancer Outcomes to Obesity and Body Weight Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C. Professor of Medicine University of Toronto Obesity Trends* Among U.S. Adults BRFSS,
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationBreast Cancer Survivorship: Physical Activity
WORKING EVERYDAY TO PROVIDE THE HIGHEST QUALITY OF LIFE FOR PEOPLE WITH CANCER Breast Cancer Survivorship: What is the Role of Diet and Physical Activity WENDY DEMARK-WAHNEFRIED, PHD, RD PROFESSOR AND
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationAnthropometry: What Can We Measure & What Does It Mean?
Anthropometry: What Can We Measure & What Does It Mean? Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, Washington, U.S.A. I have no conflicts to disclose. Anthropometry in Human
More informationExercise Guidance after a Cancer Diagnosis: Evidence and Logistics
Exercise Guidance after a Cancer Diagnosis: Evidence and Logistics Kathryn Schmitz, PhD, MPH, FACSM President Elect, American College of Sports Medicine Professor, Penn State College of Medicine Associate
More informationPhysical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review
JNCI Journal of the National Cancer Institute Advance Access published May 8, 2012 DOI: 10.1093/jnci/djs207 Published by Oxford University Press 2012. REVIEW Physical Activity, Biomarkers, and Disease
More informationLife after treatment for Ovarian Cancer: Cancer Survivorship. Anne Blaes MD, MS
Life after treatment for Ovarian Cancer: Cancer Survivorship Anne Blaes MD, MS Goals 1. To gain an understanding of potential late effects of cancer therapy 2. To gain an understanding of a cancer survivorship
More informationHealth status and Healthcare utilization of Breast cancer survivors
Health status and Healthcare utilization of Breast cancer survivors 2017.4.22 Jihyoun Lee Breast Center, department of surgery Soonchunhyang University Seoul Hospital Issues in cancer survivors Persistent
More informationLeveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationSoyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.
Soyfood Consumption and Breast Cancer Survival Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A. Objectives Brief summary of the health benefits of soyfood consumption
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationOptimal Nutritional Goals for the Cancer Survivor
W O R K I N G E V E R Y D A Y T O P R O V I D E T H E H I G H E S T Q U A L I T Y O F L I F E F O R P E O P L E W I T H C A N C E R Optimal Nutritional Goals for the Cancer Survivor W E N D Y D E M AR
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationExercise as Medicine for Cancer Management. Robert U. Newton, PhD
Exercise as Medicine for Cancer Management Robert U. Newton, PhD What is Anabolic Exercise? Repetitive movements performed against resistance Resistance limits number completed e.g. 10 reps per set (10RM)
More informationBreast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 29 OCTOBER 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Alcohol Consumption and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer: The
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationSoyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.
Soyfood Consumption and Breast Cancer Survival Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A. Objectives Brief summary of the health benefits of soyfood consumption
More informationObesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona
Obesity and Cancer Survivorship Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona Objectives Describe the relationship between obesity, weight gain
More informationNo effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial
University of North Florida UNF Digital Commons Nutrition and Dietetics Faculty Publications Department of Nutrition and Dietetics 11-2010 No effect of exercise on insulin-like growth factor (IGF)-1, insulin
More informationChapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence
Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence 2.1 BMI and Breast Cancer Risk BMI is routinely used to qualify an individual s adiposity, yet it is simply a measure
More informationHow do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian
How do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian Developing a specialist weight management programme How did we adapt dietary approaches for
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationSurvivorship and Breast Cancer in Older Patients
Survivorship and Breast Cancer in Older Patients Michelle Melisko MD Clinical Professor of Medicine UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Research support: Nektar, Novartis,
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationJournal of Clinical Oncology
Journal of Clinical Oncology Copy of e-mail Notification zlj7630 Your article (# 59822) from Journal of Clinical Oncology is available for download ===== Journal of Clinical Oncology Article no. 59822
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationPhysical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study
DOI 10.1007/s10552-010-9714-3 ORIGINAL PAPER Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study Lisa A. Cadmus Bertram
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationSurvivorship: Lifestyle Modifications of Diet and Exercise
Survivorship: Lifestyle Modifications of Diet and Exercise Alice S. Ryan, PhD Professor Division of Gerontology and Geriatric Medicine University of Maryland School of Medicine VA Senior Research Career
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationThe B-AHEAD 2 Trial. Randomised controlled trial of intermittent versus continuous energy restriction during adjuvant chemotherapy:
The B-AHEAD 2 Trial Randomised controlled trial of intermittent versus continuous energy restriction during adjuvant chemotherapy: Dr Michelle Harvie Research Dietitian The Nightingale and Prevent Breast
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationNIH Public Access Author Manuscript Breast Cancer Res Treat. Author manuscript; available in PMC 2012 February 5.
NIH Public Access Author Manuscript Published in final edited form as: Breast Cancer Res Treat. 2011 November ; 130(1): 195 205. doi:10.1007/s10549-011-1557-4. Multivitamin Use and Breast Cancer Outcomes
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 1/2019 Origination: 1/2006 Next Review: 9/2019 Policy
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationCorrelations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation Rachel Ballard-Barbash, MD, MPH Applied Research Program (ARP) Division of Cancer Control and Population
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationAgenda. Adjuvant Bisphosphonates: Ready For Prime Time? The Osteoporosis Equation. Risk Factors for Osteoporosis. Charles L.
Adjuvant Bisphosphonates: eady For Prime Time? The Osteoporosis Equation Aging, family history, race, menopause [estrogen deficiency] diet, exercise, smoking, alcohol, meds Charles L. Shapiro, MD Director
More informationConnecting Links for Reducing Risks: Understanding the impact of obesity on cancer development. Kristi Acker, DNP, FNP-BC, AOCNP, ACHPN
Connecting Links for Reducing Risks: Understanding the impact of obesity on cancer development Kristi Acker, DNP, FNP-BC, AOCNP, ACHPN Objectives 1) Identify factors that contribute to the financial burden
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationInfluence of Weight Management and Exercise on Other Outcomes
Influence of Weight Management and Exercise on Other Outcomes Melinda L. Irwin, PhD, MPH Professor of Epidemiology, Yale School of Public Health Associate Director for Population Sciences, Yale Cancer
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 9/2018 Origination: 1/2006 Next Review: 9/2019 Policy
More informationOncotype DX tools User Guide
Oncotype DX tools User Guide This guide provides an overview of the data and quick access to the Oncotype DX tools Oncotype DX tools offers two quantitative calculator tools that may be used together with
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationObesity and Breast Cancer in a Multiethnic Population. Gertraud Maskarinec, MD, PhD University of Hawaii Cancer Center, Honolulu, HI
Obesity and Breast Cancer in a Multiethnic Population Gertraud Maskarinec, MD, PhD University of Hawaii Cancer Center, Honolulu, HI Background Breast cancer incidence remains lower in many Asian than Western
More informationBody Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
JNCI J Natl Cancer Inst (2015) 107(9): djv179 doi:10.1093/jnci/djv179 First published online June 25, 2015 Article Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741
More information